

This document is an unofficial translation of the corresponding Swedish document. In the event of any discrepancies between the text contained in this document and the Swedish document, the latter shall prevail.

The board of directors' of Biotage AB (publ) report pursuant Chapter 18 Section 4 Swedish Companies Act

The Board of Directors has proposed that the 2019 Annual General Meeting resolves on a dividend of SEK 1.50 per share, which will result in an aggregate dividend of not more than SEK 97,802,676. No shares are held in treasury. With reference to this proposal, the Board of Directors is submitting this report in accordance with Chapter 18 Section 4 of the Swedish Companies Act.

Provided that the 2019 Annual General Meeting resolves in accordance with the Board of Directors' proposal regarding dividend, SEK 338,530,269 of the company's non-restricted equity will be brought forward. As of 31 December 2018, the company's non-restricted equity amounted to SEK 89,953,081. The Board of Directors utilized the authorization to issue shares granted by the 2018 Annual General Meeting and resolved on 15 January 2019, to issue new shares as part of consideration for the acquisition of PhyNexus, Inc. Following the issue of the new shares the company's restricted equity amounted to SEK 90,630,480. As of 31 December 31 2018, the company's non-restricted equity amounted to SEK 436,332,944 and the group's total equity amounted to SEK 702,180,209. The company's equity/asset ratio was 62.3 % as of 31 December 2018 following deduction of the proposed dividend (88.8 % as of 31 December 2017). The group's equity/asset ratio was 66.8 % as of 31 December 2018 following deduction of the proposed dividend (77.7 % as of 31 December 2017).

Record date for dividend is proposed to be Friday, 26 April 2019. Payment of dividend is estimated to be effectuated by Euroclear Sweden AB on Thursday 2 May 2019.

The group's equity/assets ratio is satisfactory considering that the group's operations is expected to be profitable also going forward. The liquidity is also expected to be held at satisfactory level. The dividend is not considered to imply any risk for the company or the group to meet their long-term or short-term obligations or to affect the company's ability to carry out necessary investments in the group's business

The Board of Directors' assessment is that the company's and the group's equity following dividend, will be large enough to fulfill the requirements of the scope and risks of the business conducted. Furthermore, the Board of Directors believes that these measures are reasonable considering the company's and the group's need for consolidation, liquidity and other operating conditions. The dividend is not considered to imply any risk for the company or the group to meet

their long-term or short-term obligations. These measures are not assessed to affect the company's ability to carry out necessary investments in the group's business. It is hereby noted that the Board of Directors has taken into account the acquisition of PhyNexus, Inc. at approximately SEK 191,000,000 whereof SEK 89,000,000 are expected earn-out payments during the years 2019 – 2023 based upon expected future results (recalculation to SEK is based upon an exchange ratio USD/SEK of 8.93). This transaction closed on 15 January 2019 and was funded by cash and newly issued shares, which do not in a significant way affect the liquidity of the group.

With reference to the above, it is the opinion of the Board of Directors that the proposed dividend is in line with the duty of care provision set out in Chapter 17 Section 3 Paragraphs 2 and 3 of the Swedish Companies Act.

Uppsala, 25 March 2019

Biotage AB (publ)

The Board of Directors